Abstract: AIM: To investigate the pharmacokinetics of sodium β-aescinate in cerebral damage rats induced by ischemia-reperfusion by the developed method of ELISA (enzyme-linked immunosorbent assay). METHODS: After iv injection of sodium β-aescinate (5 mg·kg^-1), the plasma concentration was determined. The pharmacokinetic parameters were accessed by the DAS. RESULTS: The profile of the plasma concentration-time was fitted with two-compartment model either in normal or in cerebral ischemia-reperfusion rats. In normal rats, T_1/2α= 0.343 h, and T_1/2β =23.325 h. In cerebral ischemiareperfusion, T_1/2α =0.854 h, and T_1/2β =34.283 h. CONCLUSION: The clearance of sodium β-aescinate in cerebral ischemia-reperfusion rats is obviously slower than that in normal rats. The pharmacokinetics of sodium β- aescinate is necessary to consider under the pathologic condition when it is used in treatment of patients of cerebral ischemic disease.

Key words: sodium β-aescinate, pharmacokinetics, enzyme-linked immunosorbent assay, cerebral ischemia